Repare Therapeutics Inc., a clinical-stage precision oncology company, has announced an exclusive worldwide licensing agreement with Debiopharm International S.A. for lunresertib, a first-in-class PKMYT1 inhibitor. Under the terms of the agreement, Repare will receive a $10 million upfront payment and may receive up to $257 million in potential milestones, along with single-digit royalties on global net sales. This agreement builds on the existing collaboration between Repare and Debiopharm to explore the synergy of lunresertib with Debio 0123, a selective WEE1 inhibitor. Debiopharm will assume sponsorship of the MYTHIC study and manage future development activities for lunresertib. Two ongoing Phase 1 trials, the LIONS trial and the POLAR trial, are expected to have readouts in the second half of 2025.